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Abstract
Background: More accurate coronary heart disease (CHD) prediction, specifically in middle-aged men, is needed to reduce
the burden of disease more effectively. We hypothesised that a multilocus genetic risk score could refine CHD prediction
beyond classic risk scores and obtain more precise risk estimates using a prospective cohort design.
Methods: Using data from nine prospective European cohorts, including 26,221 men, we selected in a case-cohort setting
4,818 healthy men at baseline, and used Cox proportional hazards models to examine associations between CHD and risk
scores based on genetic variants representing 13 genomic regions. Over follow-up (range: 5–18 years), 1,736 incident CHD
events occurred. Genetic risk scores were validated in men with at least 10 years of follow-up (632 cases, 1361 non-cases).
Genetic risk score 1 (GRS1) combined 11 SNPs and two haplotypes, with effect estimates from previous genome-wide
association studies. GRS2 combined 11 SNPs plus 4 SNPs from the haplotypes with coefficients estimated from these
prospective cohorts using 10-fold cross-validation. Scores were added to a model adjusted for classic risk factors comprising
the Framingham risk score and 10-year risks were derived.
Results: Both scores improved net reclassification (NRI) over the Framingham score (7.5%, p= 0.017 for GRS1, 6.5%, p= 0.044
for GRS2) but GRS2 also improved discrimination (c-index improvement 1.11%, p= 0.048). Subgroup analysis on men aged
50–59 (436 cases, 603 non-cases) improved net reclassification for GRS1 (13.8%) and GRS2 (12.5%). Net reclassification
improvement remained significant for both scores when family history of CHD was added to the baseline model for this
male subgroup improving prediction of early onset CHD events.
Conclusions: Genetic risk scores add precision to risk estimates for CHD and improve prediction beyond classic risk factors,
particularly for middle aged men.
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Introduction
Coronary heart disease is a leading cause of morbidity and
mortality among adults in Western societies [1]. Both lifestyle and
genetic factors contribute to the manifestation of the disease.
Current risk scores, based on age, sex and modifiable risk factors
such as blood lipid profile explain a significant proportion of
coronary heart disease (CHD) [2] Pharmacologic preventive
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therapies are aimed at those at high risk (.20% 10-year risk of
CHD). However, a substantial population attributable fraction of
CHD comes from those at intermediate risk (i.e. 5–,20% 10 years
CHD risk) and 15–20% of myocardial infarction (MI) patients
would be considered low risk using current risk scores [2].
Particularly, men and individuals with a positive family history of
coronary heart disease carry a high lifetime risk [1]. More accurate
prediction, specifically in middle-aged men, is needed to reduce
the burden of disease more effectively.
Genome wide association (GWA) studies have identified several
common genetic variants associated with modest population
attributable fractions for CHD [3]. Prediction improvement using
genetic markers must be demonstrated over and above well-
validated risk scores using standard metrics to evaluate their
performance including discrimination, calibration, risk reclassifi-
cation and, thereby, their potential clinical utility [4–5]. The most
validated genetic risk marker for CHD is on chromosome 9p21.3
[6]. It’s individual utility in CHD prediction is modest [6].
Combining the relatively small effects of individual variants into a
multilocus genetic risk score (GRS) may improve prediction and
thereby clinical decision-making for primary prevention. Howev-
er, recent efforts produced rather mixed results [7–9]. For
example, a GRS combining the effects of 101 SNPs failed to
improve prediction beyond family history in a large cohort of
women [9]. However, most of these SNPs could not be validated
in large scale GWAS to be significantly associated with CHD, until
recently 13 loci [10] were reproducibly associated with CHD but
16 new loci [11–12] have been added to this group. Other studies
have tested the value of scores based on risk alleles from smaller
subsets of SNPs, which have improved prediction in case-control
groups, but the results may not generalise to the prospective setting
[7]. Indeed, a 13 SNP GRS weighted with effect size estimates
from previous GWA studies failed to substantially improve CHD
prediction in prospective cohorts from Sweden and Finland [8] or
America [13].. Similarly a 29 SNP score provided only marginal
predictive benefit in a prospective Dutch cohort but this effect was
mainly contributed by three SNPs [14].
In this study, we devised a multilocus GRS for CHD prediction,
combining variants from 13 genomic regions, in the prospective
MORGAM (MOnica Risk, Genetics, Archiving, Monograph)
cohorts [15]. We tested the performance of GRS using both
published effect estimates from GWA studies and estimates
derived from the MORGAM cohorts. Compared with previous
studies, our analysis is based on a larger number of incident CHD
events from a wider selection of European populations with
specific focus on middle aged men.
Methods
Study population
The MORGAM project comprises .128,000 men and women
from 57 European (mainly white Caucasian) cohorts which were
harmonised and prospectively followed up for incident coronary
heart disease events [15]. For this analysis we focused on 26,221
men without MI at baseline from nine cohorts. Of these, 1736
men developed incident CHD (fatal and non-fatal) over a median
18 years follow up. From the full eligible cohort, a random
subcohort was selected independently of the case selection, with
selection probabilities depending on age. The case-cohort set
comprises the subcohort along with all cases outside the subcohort,
resulting in a total of 4818 men (1736 cases and 3082 non-cases)
for genotyping (Table 1, Figure 1) [16]. Baseline characteristics
were similar across cohorts (Table 1, Table S1).
We focused our analysis on men as this approach neutralizes the
dominant effect of gender on CHD prediction, which marginalizes
other variables in standard risk models while providing clinically
relevant information specific to men. The cohorts were measured
at baseline in a highly standardised way for total and high-density
lipoprotein (HDL) cholesterol, and blood pressure. Questionnaire
data were collected on daily smoking, history of MI at baseline,
history of diabetes blood pressure medication use and family
history of CHD [17]. The follow-up procedures of the cohorts
varied, depending on what was possible to do in each country:
linkage to hospital discharge and mortality registries, linkage to
WHO MONICA coronary event registries or active follow-up
through re-contact to the cohort participants. Possible coronary
events were validated using medical records for clinical symptoms
and signs, ECG reports, cardiac biomarkers and enzymes, and
death certificates and autopsy reports. In some of the cohorts,
where validation studies had shown good agreement, all or some
of the end-points were classified on the basis of the clinical and/or
routine death diagnoses. Incident CHD was defined as first fatal or
non-fatal CHD event, which included definite and possible acute
MI or coronary death, unstable angina pectoris, revascularization
and unclassifiable fatal events [17]. Details of the follow-up and
diagnostic procedures in each cohort have been published [18].
SNP selection and genotyping
We chose SNPs that exceeded a significance threshold of
p,561028 for association with CHD or MI and were replicated
in (at least two) large GWAs studies. 12 SNPs and a haplotype
comprising four SNPs from the LPA locus met these criteria at
study initiation (see Table 2 for references). SNP genotyping was
carried out on the MassARRAY System with iPLEX Gold
chemistry (Sequenom, California) as previously described [22].
Statistical analysis
Missing genetic data (which ranged from 10.2% to 21.4%
(mean 13.1%) per SNP) were multiply imputed within each cohort
using WinBUGS [23], with outcome information included in the
imputation model to avoid attenuation of estimated effects in later
analyses [24]. Multiple imputation is a statistical technique distinct
from imputation of SNP information based on linkage disequilib-
rium. The main purpose of multiple imputation, rather than to
estimate individual predictor values, is to estimate the uncertainty
about the missing values, while at the same time minimising the
information loss compared to complete case analysis (see
Supporting Information S1). Because of the case-cohort design,
all analyses used inverse selection probability weighting to relate
the results back to the larger cohort level.
Individual SNP/haplotype association analysis
We tested the association between individual SNPs/haplotypes
and incident CHD events using Cox proportional hazards models
adjusted for cohort and geographical region and a score of classic
risk factors at baseline based on Framingham coefficient of age,
daily smoking, systolic blood pressure, total cholesterol, HDL-
cholesterol, and prevalent diabetes [25]. We refer to this as the
Framingham Score. In the Framingham study these risk estimates
gave a c-index of 0.742 for CHD [25] We applied these
coefficients in the MORGAM data, but allowed the baseline risk
to vary between cohorts (i.e. absolute cohort specific risk levels
were estimated from MORGAM data), resulting in a c-index of
0.7428. The relative risk in terms of the Framingham score was
higher in the ATBC cohort which is in part due to the larger
percentage of smokers in this cohort (Figure S1). However, the
genetic score is evenly distributed across the cohorts (Figure S2)
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and uncorrelated with the Framingham score, so the differences in
cohort characteristics are unlikely to be a source of confounding in
the genetic risk score analyses. For the LPA locus, we used
FastPHASE to multiply impute LPA haplotype pairs separately for
cases and non-cases within each cohort [26]. We estimated the
effect sizes from the LPA haplotypes using a model that
simultaneously included all haplotypes compared to the most
frequent AATC haplotype [21]. In the Cox regression models all
missing data were handled using multiple imputation. However, in
validation of the prediction models we limited the amount of
missing data by restricting the validation set to men with complete
genotypes for at least 11 of the 15 SNPs (N= 4209). In the Cox
proportional hazards models non-cases were weighted by the
inverse of their subcohort selection probabilities while cases were
included with unit weights [16]. Time-to-event models were fitted
using the survival package of R statistical software.
Development of genetic risk scores
We used two approaches for deriving the genetic risk scores.
The first derived a score for MORGAM participants using effect
sizes from previous GWA studies (Genetic Risk Score 1; GRS1). A
‘weighted’ risk score was calculated for each subject by adding the
number of risk alleles by SNP, multiplied by the associated effect
size (log odds ratio) previously reported in the literature. Chosen
SNPs were not in linkage disequilibrium (Table S2). The score
assumed an additive risk model and no interaction between the
SNPs. GRS1, comprised 11 SNPs and two haplotypes (Table S3)
along with the Framingham score for classic risk factors.
Our second approach derived the coefficients for the score
directly from the MORGAM prospective dataset. Score develop-
ment was based on 1736 cases and 3082 non-cases. All SNPs were
added in a model incorporating the Framingham score (GRS2).
We extended the analysis by applying lasso, a penalized regression
technique that carries out variable selection and estimates the
coefficients of selected variables [27]. This form of penalization for
overfitting removes redundant predictors from the model. SNPs
with non-zero coefficients comprised score 3 (GRS3) along with
the Framingham score. Lasso models were estimated using the
glmnet package of R. Ten-year risk estimates for incident CHD
events were derived from the fitted Cox regression models using
the survival package of R.
Risk model assessment
We used the MORGAM dataset to derive and test GRS2 and
GRS3. The predictive value of the data-derived scores was
evaluated using 10-fold cross-validation. This avoids using the
same individuals in developing and testing the model. The dataset
was split randomly into 10 equal sized validation sets and the
prediction model was fitted to each of the 10 datasets obtained by
leaving out each of the validation sets in turn, with the 10-year risk
estimates for the omitted group derived from the model fitted to
the remaining data [28]. While cross-validation is not a complete
substitute for external validation, it utilises available data more
efficiently than split sample validation [28] (Supporting Informa-
tion S1). Validation of the data derived scores are based on
individuals which have 10 years of follow up information (first 10
years from cohorts) comprising 632 cases and 1361 non-cases. To
test whether the three genetic risk scores (GRS1–3) improve
prediction, a baseline model with the Framingham score was
compared to a model with each genetic risk score incorporated in
the baseline model. Models were tested using the c-index
improvement, integrated discrimination improvement (IDI) and
net reclassification improvement (NRI) according to recently
suggested risk limits 0% to ,5%, 5% to ,10%, 10% to ,20%
and $20% for 10 year risk limits [29]. In addition, ‘Clinical’ NRI
quantifies the improvement in prediction in the intermediate risk
group (5–20%) which incorporates a correction for the expected
value of improvement [30]. This test measures the reclassification
where only individuals in the intermediate group are tested with
the GRS and have their risk recalculated. For exploring the effect
of adding family history of CHD on the models, we studied the
cohort definitions of family history (Table S4) and a separate
coefficient for the family history covariate was estimated for each
cohort. This was added to the Framingham model with genetic
risk scores subsequently added to this model.
GRS and event free survival analysis
Kaplan-Meier curves were plotted to depict CHD free survival
by quarters of the genetic risk scores, and the log rank test was
used to assess the differences. The log rank test estimated
differences in survival curves across quarters of the externally
derived GRS1 until age 70 and 10 years survival. While it was
appropriate to calculate the significance of GRS1 as the risk sets
were determined using externally derived coefficients we did not
calculate it for the cross-validated scores.
Figure 1. Schematic diagram of the case-cohort design in
MORGAM. Outline of the selection of individuals in the MORGAM
dataset. The subcohort and all CHD cases who were genotyped
(N = 4818) were chosen from the full cohort. We restricted the validation
analysis to 4209 men with complete genotype data for .= 11 SNPs
with the remaining SNP data multiply imputed.
doi:10.1371/journal.pone.0040922.g001
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Population attributable fraction
Population attributable fraction (PAF) estimates the genetic risk
scores’ contribution in explaining CHD incidence in the
MORGAM population. PAFs were calculated with respect to a
hypothetical population genetic profile truncated from above the
GRS population average. We defined population attributable risk
as the population risk minus the modified risk when the GRS was
set to the population mean, for those with above average GRS.
Population attributable fraction is the ratio of this difference to the
overall population risk, indicating the proportion of the risk
‘attributable’ to genetic variation. For reference, we also calculated
PAF for continuous classic risk factor variables.
Results
Individual SNP/haplotype analysis
Cox regression analysis revealed four significant associations for
additive allele effects with incident CHD in a model adjusting for
cohort and Framingham score: rs1333049 (9p21); rs1256453
(PHACTR1); rs2048327 (LPA) and rs3008621 (MIA3) (Table 2).
Unadjusted associations are given in Tables S5 and S6. Because
rs9818870 (MRAS) was not significantly associated with CHD and
not typed in the Swedish cohort, we excluded it from our GRS
models. Sensitivity analysis excluding the Swedish cohort showed
that the addition of this SNP did not appreciably change the
results (see Supporting Information S1, Table S7).
Genetic risk scores
Genetic risk score 1. The baseline model based on the
Framingham Score achieved a c-index of 0.743. Adding GRS1 to
the baseline model did not significantly improve discrimination (c-
index 0.752, p=0.11). However, risk classification improved
significantly (NRI by 7.5% p=0.017 and IDI by 0.4% p=0.007)
in the entire sample of men (Table 3, Table S8 for full
reclassification statistics). Clinical NRI for men in the intermediate
risk group only (431 cases, 664 non-cases) was not significant (6%,
p=0.17).
Genetic risk scores 2 and 3. Score development (GRS2 and
GRS3) was based on 1736 cases and 3082 non-cases. The
validation set comprised 632 cases and 1361 non-cases from the
first 10 years’ of follow-up of the cohorts with a follow-up period of
at least 10 years. For example, this was related to approximately
715 cases and 9575 non-cases in the full cohort using the case-
cohort weighting incorporating censoring.
GRS2 comprised 15 SNPs with coefficients derived from a Cox
model fitted to the MORGAM dataset (Table S3). While the LPA
haplotypes were significantly associated with CHD in case-control
studies they were not significant in our prospective dataset
(Table 4) (or in a recent study evaluating CHD risk in diabetics
[31]) and did not improve the data derived scores (data not
shown). Instead, we utilised individual SNP data only at the LPA
locus. GRS2 based on internally determined weight estimates gave
broadly similar findings to GRS1. The c-index improved by
1.11% which was marginally significant (p=0.048) when added to
the baseline model. The overall NRI was 6.5% (p=0.044) and IDI
was 0.7% (p=0.0004), almost all of this due to upward
reclassification of cases (Table 3, Table S8). For the 431 cases
and 664 non-cases initially in the intermediate risk category,
clinical NRI was not significant (5.1% p=0.2) but followed the
trend in the whole group with cases correctly reclassified upwards
(6.1%, p=0.048). This indicates that while reclassification is
mainly beneficial in the low and high risk groups, intermediate
cases are correctly reclassified upwards to the high risk group.
Lasso regression identified 8 variants with non-zero coefficients
incorporated into genetic risk score 3 (Table S3). GRS3
demonstrated an improvement in the c-index from 0.742 to
0.755 (p=0.0044), with a gain in NRI of 6% (p=0.039) and an
IDI of 0.5% (p=0.0009 Table 3, Table S8). The clinical NRI for
the intermediate risk men was not significant 5.6%, p=0.16) but
with cases correctly reclassified upward 5.5% p=0.03). The c-
index improvement of 1.22% resulting from addition of GRS3,
compared to 1.11% from GRS2, indicates that only a small subset
of 8 risk alleles are discriminatory in our models.
Subgroup analysis in middle-aged men
We validated the prediction models in men aged 50–59 at
baseline (436 cases and 603 non-cases). This controls the
dominating effect of age on risk and indicates the potential benefit
attainable in this group. Here, the Framingham risk score
produced a c-index value of 0.661. C-index improvement was
2.6%, (p=0.007) for GRS1, 2.8%, (p=0.0038) for GRS2 and
2.6%, (p=0.001) for GRS3. Corresponding NRI were 13.8%
(p=0.0022) for GRS1, 12.5%, (p=0.0069) for GRS2 and 10.7%,
(p=0.015) for GRS3 with benefit mainly in cases reclassified
upwards (Table S9).
Addition of family history data to genetic risk scores
Adding family history to the baseline model for the whole group
(627 cases, 1342 non-cases excluding missing information)
improved NRI (5.5%, p=0.023) but not the c-index (Table
S10). Adding GRS1 or GRS2 to this model did not improve
discrimination statistics. The estimated effect sizes for the family
history covariate differed between the cohorts, being lower for
FINRISK, a difference which cannot be explained by disparate
definitions of family history. We thus focused on 50–59 year old
men, since family history should become apparent by this stage
and exclude parents of younger participants which have spent less
time at risk of premature MI. The addition of family history
information to the subgroup of men aged 50–59 significantly
Table 3. Comparison of models with and without genetic risk
scores.
NRI IDI Clinical NRI
Value SE p Value p Value p
FRS+GRS1
Cases 0.049 0.028 0.074 0.004 0.020 0.034 0.291
Non-cases 0.025 0.021 0.230 0.001 0.398 20.029 0.435
0.075 0.031 0.017 0.004 0.007 0.063 0.175
FRS+GRS2
Cases 0.071 0.025 0.005 0.007 0.0003 0.061 0.042
Non-cases 0.007 0.021 0.755 0.0001 0.903 0.01 0.769
0.065 0.032 0.044 0.007 0.0004 0.051 0.269
FRS+GRS3
Cases 0.062 0.023 0.008 0.005 0.001 0.056 0.037
Non-cases 0.002 0.018 0.931 0.0002 0.721 20.001 0.977
0.060 0.029 0.039 0.005 0.0009 0.056 0.16
NRI measures reclassification across risk groups 0% to ,5%, 5% to ,10%, 10%
to ,20% and $20%, Clinical NRI measures the improvement for those in the
middle (5 to ,20%) risk group who are reclassified after inclusion of GRS. NRI
Net Reclassification Index, IDI Integrated Discrimination Improvement, FRS+GRS
Framingham risk score+genetic risk score.
doi:10.1371/journal.pone.0040922.t003
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improved NRI (8.8%, p=0.016) (Table 5). However it did not
significantly improve the c-index (1.7%, p=0.06) reflecting the
relative insensitivity of this measure. Adding the genetic scores to a
baseline Framingham model and family history continued to
improve reclassification. Net reclassification was 9.8% (p=0.019)
for GRS1 and 13.2% (p=0.015) for GRS2 with significant upward
reclassification of cases (Table 5) indicating predictive improve-
ment of early onset CHD events.
Genetic risk scores and event free survival analysis
Event free survival curves illustrate differences in risk of incident
CHD across the quarters for GRS1 and GRS2 (Figure 2 A and B).
The chance of reaching age 70 years event free was 80% in the
quarter with the highest GRS1 and 86% in those with the lowest
GRS1 (log rank test p=0.001 for the difference). The chance of
surviving ten years event free from the study baseline was 91% in
the highest GRS1 group and 94% in the lowest GRS1 group
(p=0.001). Based on Figure 2, while GRS1 distinguishes the first
and second quarter from the third and fourth groups, GRS2
clearly distinguishes the fourth or highest risk group from the other
groups in terms of elevated risk. We also estimated event free 10-
year survival in the 50–59 year old subgroup, as well as in the
intermediate (5–20%) risk category based on the Framingham
score. In the 50–59 year olds the 10-year survival probability in the
highest (lowest) GRS1 quarter was 90% (94%, p=0.003), and in
the intermediate risk category 88% (91%, p=0.01).
Population attributable fraction
PAFs calculated the observed model-based risk compared to a
hypothetical situation where men with above average genetic risk
were moved to the population average genetic risk. The
distribution of risk scores across the MORGAM cohorts were
similar (Figure S2). The PAF for GRS1 was 12.1%, which serves
only as a benchmark since it represents the external coefficients
and not effects observed in the MORGAM data. However, PAFs
for GRS2 and GRS3 were comparable to this: 11.9% (95% C.I.
8.8–15.4%) and 9.5% (5.1–13.6%) respectively. These PAF
estimates are similar to the PAFs observed in MORGAM cohorts
for HDL cholesterol (12.3% (95% C.I. 9.3–15.7%) and systolic BP
(12.1% (9.5%–15.4%) while the PAF for diastolic BP and BMI
were lower, (4.9% and 5.9%). (Table S11).
Discussion
Recent success of genome wide association studies in identifying
variants affecting disease risk stirred much debate about the utility
of genetic risk scores for prediction of complex diseases. Scepticism
was fuelled by results of often under-powered studies. Here, we
demonstrate that genetic risk scores can meaningfully refine risk
classification for coronary disease in men, particularly aged 50–59
years, when added to the information derived from conventional
cardiovascular risk factors.
Other prospective cohorts evaluating the addition of genetic risk
scores to classic risk factors have found only marginal benefits. A
13 SNP weighted score failed to significantly improve the c-index
or NRI but showed marginal benefit for IDI (0.004, p=0.0006) in
Finnish and Swedish cohorts [8]. A weighted SNP score based on
29 CHD loci (although not directly comparable included the 13
loci used in our study) provided marginal reclassification benefit
(NRI 2.8%, p=0.03) in a prospective Dutch cohort but this benefit
was mainly contributed by three SNPs [14]. A 13 SNP score failed
to significantly improve the c-index or category led NRI but
showed marginal reclassification benefit for continuous NRI (19%
95% C.I. 0.02–0.34) in an American cohort with European
Table 4. Association between LPA haplotypes and CHD in MORGAM.
rs2048327 rs3127599 rs7767084 rs10755578 Frequency
Haplotype
combination
in ref 21
HR reported
in ref
CHD (1736 cases, 3082
non cases)
Pooled HR (95% C.I.) p value
A A T G 0.13 TTTG 0.99 (0.85–1.16) 0.94
G G T C 0.03 CCTC 1.8 1.19 (0.88–1.61) 0.26
G G C G 0.14 CCCG 1.12 (0.97–1.31) 0.12
A A T C 0.03 TTTC 0.91 (0.65–1.27) 0.56
A G T G 0.14 CTTG 1.2 1.14 (0.98–1.33) 0.09
G G T G 0.02 CCTG 1.04 (0.74–1.47) 0.81
While MORGAM associations conditioned on a different allele set, haplotypic combinations are consistent with those reported in ref which are given here for
comparison. Association was tested with a model adjusted for cohort and Framingham coefficients. Haplotypic ORs were used as coefficients for GRS1.
doi:10.1371/journal.pone.0040922.t004
Table 5. Addition of family history information to genetic risk
scores.
NRI IDI
Value SE p Value p
FRS+FH
Cases 0.031 0.025 0.169 0.008 0.0005
Non-cases 0.053 0.026 0.044 0.001 0.469
0.088 0.036 0.016 0.006 0.018
FRS+FH+GRS1
Cases 0.065 0.035 0.065 0.006 0.0065
Non-cases 0.033 0.031 0.033 0.001 0.588
0.098 0.042 0.019 0.007 0.003
FRS+FH+GRS2
Cases 0.142 0.041 0.0005 0.018 0.001
Non-cases 0.011 0.039 0.787 0.001 0.683
0.132 0.054 0.015 0.018 0.0025
Reclassification results comparing a baseline model including family history
(FH); to models including genetic risk scores for men aged 50–59.
doi:10.1371/journal.pone.0040922.t005
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Figure 2. Kaplan-Meier curves may better predict those with premature CHD. Survival curves assessing the time to incident CHD with
increasing age across four GRS categories for GRS1 (A) and GRS2 (B). Survival probabilities are truncated from 0–0.4.
doi:10.1371/journal.pone.0040922.g002
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ancestry [13]. The addition of the newly discovered 16 SNPs failed
to add significantly to prediction [13]. Our findings in the
MORGAM prospectively followed European cohorts offer stron-
ger effect estimates than observed in these recent studies [8,13–14]
which may need explanation. Firstly, we focused on men since the
statistical power for showing effects in addition to classical risk
factors may be enhanced when gender is excluded as a
confounding factor. Moreover, our study included about 50%
more incident coronary cases from across Europe [8,13–14]
Finally, we employed relative effect estimates from the largest
GWA study performed to date for CHD [11], which were 1–6
percentage points smaller and thus resulted in more conservative
estimates than those used by previous studies [8,13].
Genetic risk scores modestly improve prediction and
particularly for middle-aged men
Applying the genetic risk score to all men reclassified between
6–7.5% of our cohort and in the subgroup of men aged 50–59
years reclassified between 10.7–13.8% with benefit mainly
observed in identifying future cases. Age typically has a large
impact on discrimination statistics, so when we limit the age range
to 50–59 we limit the effect of age as the main CHD risk factor on
the prediction models and the predictions become more sensitive
to the effect of other factors such as the SNPs. The difference in
the c-index between all men (0.743) and 50–59 year old men
(0.661) is not widely recognised in clinical decision making but
highlights the impact of the scores in this subgroup. From a clinical
perspective, refinement in this group can aid decisions to initiate
preventive measures and especially lifelong blood pressure or lipid
lowering (statin) drug treatment which can be most challenging
from an individual perspective and societal affordability.
Family history is an easily ascertainable risk factor, albeit
sometimes uncertain [1]. A key requirement for any genetic risk
score is that it should add predictive value over and above a family
history [9]. As the reliability of family history may vary by age-
group we focused this analysis on middle-aged men aged 50–59
where any family predisposition should have become apparent. In
this subset, we found that the genetic risk scores improved
reclassification even incorporating family history indicating that
the two provide complementary and additive information on risk
prediction.
While the effect of each risk allele is relatively modest, their
importance to CHD development is significant, since their
prevalence ranges from 10% to 87% in Europeans (Table 2).
Survival curves illustrate that 25% of European men who carry the
most risk alleles have a 9% risk of CHD over a 10 year period as
compared to only 6% of those in the lowest quartile. From another
perspective, a 20% risk of CHD is reached by age 67 years in those
with the highest genetic risk compared to age 74 years by those
with the lowest genetic risk score. The population attributable
fraction for genetic risk as estimated by the score ranged from 9.8–
12.7% which is similar to other risk factors such as HDL
cholesterol, and systolic BP and highlights that currently identi-
fiable genetic risk makes an important contribution to overall
CHD risk.
Comparison of the performance of genetic risk scores
and biomarker risk scores
Novel blood biomarkers can measure subclinical features of
cardiovascular disease capturing genetic and non-genetic compo-
nents of disease and may provide an alternative to large scale
population risk stratification. The MORGAM project found that
the addition of a biomarker score comprising three novel
biomarkers (NtProBNP, CRP, sensitive Troponin I) to a classic
risk factors model improved 10-year risk estimation for cardio-
vascular events in middle aged European populations [32]. The
biomarker risk model as well as the baseline risk model comprising
classic risk factors were derived from FINRISK but externally
validated in a subgroup of men aged 50–59 years in PRIME
Belfast giving a c-index value of 0.67 for the baseline risk model.
This value is similar to the baseline risk model based on the
Framingham score for the 50–59 year old men in the present study
which resulted in a c-index of 0.661. The similarity of the
validation population in this biomarker study and the 50–59 year
old validation subgroup allows drawing comparison between the
two sets of results. The biomarker model resulted in a c-index
improvement of 3% (p=0.004) with NRI of 11% (p=0.0008)
which is very similar to the 2.6–2.8% improvement in the c-index
and 10–13.7% improvement in NRI for the genetic risk scores.
Because the genotypes of genetic risk scores are invariant, those
with higher GRS may predispose individuals to disease earlier
resulting in gradual increases in biomarker levels compared to
those with lower GRS. Genetic risk scores could facilitate risk
assessment earlier in life than is possible with phenotype-based
tests when knowledge of classic risk factors is limited. However,
given the heterogeneity in the behavioural responses to genetic risk
perception [33], a full decision analysis would be needed to assess
the cost effectiveness of screening middle aged men at the
population level.
Comparison of the performance of genetic risk scores as
a predictor of CHD
We studied three genetic risk scores: GRS1 used effect estimates
from previous GWA case-control studies, and two data-derived
scores, GRS2 and GRS3, based on effect estimates from our
prospectively collected data. Effect-sizes from GWA studies, such
as that used in GRS1, may overestimate the relative risk derived
from a combination of SNPs, since they often concern SNPs which
are ‘‘winners’’ from a large discovery selection. Furthermore, most
GWA studies are based on prevalent cases and the strength of the
observed (and real) association of variants may differ between
incident and prevalent disease. GRS2 was developed to allow for
these potential confounders. GRS3 determined whether a more
parsimonious sets of variants provided equivalent discrimination to
the larger SNP set. All three scores improved 10 year CHD
prediction in men in terms of reclassification, beyond that possible
with baseline classic risk factors, while the data derived scores also
improved the c-index significantly. While both approaches
displayed differences in predicting risk, the overall performance
was similar suggesting that adding predictive SNPs to prognostic
models may be beneficial even if the effect estimates are not
perfectly accurate. The lasso method, resulted in a more
parsimonious score (GRS3) which had comparable predictive
power to GRS2, indicating that model improvement was mostly
due to 8 SNPs.
Study strengths and limitations
Despite studying a large representation of the European
population, further validation is required in larger populations
with different levels of absolute risk and other ethnic groups. This
applies specifically to GRS2 and GRS3, in which effect estimates
were derived in the same population. Moreover, the list of genetic
variants associated with CHD is likely to increase such that our
scores do not capture the full potential of incorporating genetic
information. Thus, our findings can be only a starting point for
future analyses with other cohorts to refine the predictive value of
such genetic scores.
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Conclusions
Our findings demonstrate that adding a genetic risk score to
classic risk factors may improve CHD prediction. Moreover,
future attempts to add precision to a score may be of greater
benefit to population subgroups [31], here especially in middle-
aged men. As the costs of obtaining genetic information fall,
incorporating such information could make an important contri-
bution in more accurately directing primary prevention measures
and reducing the burden of CHD.
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